Absci (ABSI) Corporate presentation summary

AI-driven drug discovery platform

• Integrated AI and automated wet-lab platform enables rapid de novo antibody design and optimization for therapeutics, leveraging a 77,000 ft² automated facility and a multidisciplinary team with deep AI and drug development expertise.

• Platform delivers faster and more capital-efficient drug discovery cycles, reducing timelines from 5-6 years to 24 months and costs from $50-100M to $10-15M compared to large pharma.

• AI models can design antibodies against challenging targets with minimal prior data, enabling discovery for difficult-to-drug epitopes and rapid lead optimization.

• Lab-in-the-loop validation ensures AI-designed antibodies meet criteria for binding, developability, and manufacturability.

• Over 25 partnered programs with leading pharma and biotech companies, including AstraZeneca, Merck, and Caltech.

Clinical pipeline and lead programs

• ABS-201, an anti-prolactin receptor antibody, is in Phase 1/2a trials for pattern hair loss (PHL) with interim proof-of-concept readout expected in 2H 2026.

• ABS-201 is also being developed for endometriosis, with Phase 2 initiation anticipated in Q4 2026 and a differentiated, non-hormonal mechanism of action.

• ABS-101 for inflammatory bowel disease (IBD) has demonstrated improved half-life and tissue penetration and is ready for partnering.

• Multiple early-stage programs in immunology, inflammation, and metabolism are advancing, with several assets ready for partnering.

ABS-201 for pattern hair loss (PHL)

• Addresses a significant unmet need, with ~80M Americans affected and limited, outdated FDA-approved therapies.

• PRLR inhibition offers a novel mechanism, promoting hair regrowth, durability, and safety, supported by human genetics and preclinical models.

• Preclinical and ex vivo studies show superior efficacy to minoxidil and long-lasting effects post-treatment.

• Market research indicates strong commercial demand, with a potential US TAM >$25B and global TAM >$40B.

• Phase 1/2a trial interim data show favorable safety, tolerability, and PK, supporting a convenient dosing profile of 2-3 injections over six months.